SEC Info - Orthofix Medical Inc. - ‘10-Q’ for 6/30/16

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    488K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
11: R1          Document and Entity Information                     HTML     39K 
12: R2          Condensed Consolidated Balance Sheets               HTML     89K 
13: R3          Condensed Consolidated Balance Sheets               HTML     30K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML    133K 
                and Comprehensive Income (Loss)                                  
15: R5          Condensed Consolidated Statements of Cash Flows     HTML     62K 
16: R6          Nature of operations, basis of presentation and     HTML     32K 
                recently issues accounting pronouncements                        
17: R7          Inventories                                         HTML     46K 
18: R8          Long-term debt                                      HTML     23K 
19: R9          Derivative instruments                              HTML     68K 
20: R10         Fair value measurements                             HTML    180K 
21: R11         Accumulated other comprehensive loss                HTML     71K 
22: R12         Earnings per share                                  HTML     58K 
23: R13         Share-based compensation                            HTML     26K 
24: R14         Income taxes                                        HTML     25K 
25: R15         Business segment information                        HTML    207K 
26: R16         Contingencies                                       HTML     48K 
27: R17         Share repurchase plan                               HTML     22K 
28: R18         Nature of operations, basis of presentation and     HTML     32K 
                recently issues accounting pronouncements                        
                (Policies)                                                       
29: R19         Inventories (Tables)                                HTML     46K 
30: R20         Derivative instruments (Tables)                     HTML     65K 
31: R21         Fair value measurements (Tables)                    HTML    172K 
32: R22         Accumulated other comprehensive loss (Tables)       HTML     67K 
33: R23         Earnings per share (Tables)                         HTML     55K 
34: R24         Business segment information (Tables)               HTML    203K 
35: R25         Nature of operations, basis of presentation and     HTML     21K 
                recently issues accounting pronouncements -                      
                Additional Information (Detail)                                  
36: R26         Inventories - Schedule of Inventories (Detail)      HTML     31K 
37: R27         Long-Term Debt - Additional Information (Detail)    HTML     35K 
38: R28         Derivative Instruments - Schedule of Fair Values    HTML     28K 
                of Derivative Instruments (Detail)                               
39: R29         Derivative Instruments - Schedule of Gain (Loss)    HTML     25K 
                Recognized in Other Comprehensive Income (Loss)                  
                (Detail)                                                         
40: R30         Fair Value Measurements - Schedule of Financial     HTML     53K 
                Assets and Liabilities Measured at Fair Value on                 
                Recurring Basis (Detail)                                         
41: R31         Fair Value Measurements - Additional Information    HTML     42K 
                (Detail)                                                         
42: R32         Fair Value Measurements - Schedule of               HTML     28K 
                Reconciliation of Debt Securities (Detail)                       
43: R33         Accumulated Other Comprehensive Loss - Components   HTML     46K 
                of Changes in Accumulated Other Comprehensive Loss               
                (Detail)                                                         
44: R34         Accumulated Other Comprehensive Loss - Components   HTML     35K 
                of Changes in Accumulated Other Comprehensive Loss               
                (Parenthetical) (Detail)                                         
45: R35         Earnings Per Share - Schedule of Reconciliation of  HTML     29K 
                Weighted Average Shares Used in Calculation of                   
                Basic and Diluted Net (Loss) Income Per Share                    
                (Detail)                                                         
46: R36         Earnings Per Share - Additional Information         HTML     28K 
                (Detail)                                                         
47: R37         Share-based Compensation - Additional Information   HTML     31K 
                (Detail)                                                         
48: R38         Income Taxes - Additional Information (Detail)      HTML     27K 
49: R39         Business Segment Information - Additional           HTML     20K 
                Information (Detail)                                             
50: R40         Business Segment Information - Schedule of Net      HTML     34K 
                Sales by SBU Reporting Segment (Detail)                          
51: R41         Business Segment Information - Summary of Net       HTML     53K 
                Margin as Gross Profit Less Sales and Marketing                  
                Expense by SBU Reporting Segment (Detail)                        
52: R42         Contingencies - Additional Information (Detail)     HTML     41K 
53: R43         Share Repurchase Plan - Additional Information      HTML     34K 
                (Detail)                                                         
55: XML         IDEA XML File -- Filing Summary                      XML     99K 
54: EXCEL       IDEA Workbook of Financial Reports                  XLSX     50K 
 5: EX-101.INS  XBRL Instance -- ofix-20160630                       XML   1.55M 
 7: EX-101.CAL  XBRL Calculations -- ofix-20160630_cal               XML    116K 
 8: EX-101.DEF  XBRL Definitions -- ofix-20160630_def                XML    272K 
 9: EX-101.LAB  XBRL Labels -- ofix-20160630_lab                     XML    639K 
10: EX-101.PRE  XBRL Presentations -- ofix-20160630_pre              XML    492K 
 6: EX-101.SCH  XBRL Schema -- ofix-20160630                         XSD    104K 
56: ZIP         XBRL Zipped Folder -- 0001564590-16-021905-xbrl      Zip     94K

‘R15’ — Business segment information

This is an IDEA Financial Report. [ Alternative Formats ]

Business segment information

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Business segment information

10. Business segment information

The Company has four strategic business units (“SBUs”), which are comprised of BioStim, Biologics, Extremity Fixation, and Spine Fixation supported by corporate activities. The primary metric used in managing the Company is net margin, which is defined as gross profit less sales and marketing expense. The Company neither discretely allocates assets, other than goodwill, to its operating segments nor evaluates the operating segments using discrete asset information.

The tables below present net sales for continuing operations by SBU reporting segment. Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution^®, Trinity ELITE^® and Versashield™ in our Biologics segment.

	Three Months Ended June 30,
(U.S. Dollars, in thousands)	2016		2015		Reported Change

BioStim	$	44,758	$	40,703		10.0	%
Biologics		14,256		15,274		(6.7	)%
Extremity Fixation		26,817		25,594		4.8	%
Spine Fixation		18,244		19,383		(5.9	)%
Total net sales	$	104,075	$	100,954		3.1	%

	Six Months Ended June 30,
(U.S. Dollars, in thousands)	2016		2015		Reported Change

BioStim	$	85,802	$	78,403		9.4	%
Biologics		28,350		29,235		(3.0	)%
Extremity Fixation		51,526		47,409		8.7	%
Spine Fixation		37,076		35,669		3.9	%
Total net sales	$	202,754	$	190,716		6.3	%

The table below presents net margin, which is defined as gross profit less sales and marketing expense, by SBU reporting segment for the three and six months ended June 30, 2016 and 2015:

	Three Months Ended June 30,						Six Months Ended June 30,
(U.S. Dollars, in thousands)	2016			2015			2016			2015

Gross profit	$	81,560		$	79,044		$	158,103		$	149,467
Less: Sales and marketing		(46,037	)		(42,946	)		(90,853	)		(87,231	)
Total net margin	$	35,523		$	36,098		$	67,250		$	62,236

BioStim		18,577			16,787			34,988			30,800
Biologics		6,719			7,285			12,823			13,229
Extremity Fixation		8,162			9,149			15,340			16,165
Spine Fixation		2,203			3,173			4,539			2,644
Corporate		(138	)		(296	)		(440	)		(602	)
Total net margin		35,523			36,098			67,250			62,236
General and administrative		17,954			22,506			34,672			44,075
Research and development		6,792			6,451			14,428			12,296
Restatements and related costs		545			2,213			790			8,129
Charges related to U.S. Government resolutions		12,870			–			12,870			–
Operating (loss) income	$	(2,638	)	$	4,928		$	4,490		$	(2,264	)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References + Details

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

Filed on:	8/1/16	8-K
For Period end:	6/30/16
	6/30/15	10-Q, 4
		List all Filings

↑Top

Filing Submission 0001564590-16-021905 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Orthofix Medical Inc. – ‘10-Q’ for 6/30/16 – ‘R15’

On: Monday, 8/1/16, at 4:16pm ET · For: 6/30/16 · Accession #: 1564590-16-21905 · File #: 0-19961

Previous ‘10-Q’: ‘10-Q’ on 4/28/16 for 3/31/16 · Next: ‘10-Q’ on 10/31/16 for 9/30/16 · Latest: ‘10-Q’ on 5/7/24 for 3/31/24

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘R15’ — Business segment information

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Orthofix Medical Inc. – ‘10-Q’ for 6/30/16 – ‘R15’

On: Monday, 8/1/16, at 4:16pm ET · For: 6/30/16 · Accession #: 1564590-16-21905 · File #: 0-19961

Previous ‘10-Q’: ‘10-Q’ on 4/28/16 for 3/31/16 · Next: ‘10-Q’ on 10/31/16 for 9/30/16 · Latest: ‘10-Q’ on 5/7/24 for 3/31/24

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘R15’ — Business segment information

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents